Monopar Posts $6.2M Q3 Loss, $129.4M Cash, NDA Submission Weeks Away
MNPR sits 40% above its 52-week low of $50.07.
Summary
Monopar reported a $6.2 million third-quarter loss and $129.4 million in cash, enough to fund operations into 2028, while saying its rolling NDA submission for Wilson disease drug ALXN1840 should be complete within weeks.
Key Events · Earnings and Guidance · MNPR
-
Q3 Loss Widens on Launch Prep
Net loss was $6.2 million, or $0.72 per share, versus $3.4 million, or $0.48 per share, a year earlier. R&D rose to $4,436,543 from $2,589,749, and G&A to $3,031,302 from $1,503,326.
-
Cash Funds Operations Into 2028
Cash, cash equivalents and investments totaled $129.4 million at September 30, 2026, which the company expects to support operations through at least March 31, 2028.
-
ALXN1840 NDA Nears Completion
The rolling NDA submission for ALXN1840 in Wilson disease, initiated July 22, 2026, is on track to be completed within the next several weeks. FDA acceptance and approval timing are not yet determined.
-
AASLD Data Show Residual Disease Burden
Baseline FoCus Phase 3 findings presented November 8, 2026, showed 39% cirrhosis and 79% neurologic symptoms in treatment-experienced patients, with only 47% within the guideline copper target range.
Analysis · MNPR · Life Sciences
The quarter itself is unremarkable: the loss widened to $6.2 million from $3.4 million as R&D and G&A scaled up for a commercial launch. What matters is the balance sheet and the regulatory clock. With $129.4 million in cash, operations are funded through at least March 31, 2028, so there is no near-term financing need, and the rolling NDA for ALXN1840 in Wilson disease is expected to be complete within weeks. That filing is the binary event for this stock: acceptance and eventual approval of a first-in-class drug with no approved competitor in a rare disease. Against that, insiders have been steady sellers under pre-set 10b5-1 plans, which is worth noting but is programmatic rather than a change in conviction.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MNPR was trading at $70.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $481.5M. The 52-week trading range was $50.07 to $124.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.